Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Non-Current Assets (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of Non-Current Assets data on record, last reported at $23.4 million in Q3 2025.

  • For Q3 2025, Non-Current Assets fell 2.98% year-over-year to $23.4 million; the TTM value through Sep 2025 reached $23.4 million, down 2.98%, while the annual FY2024 figure was $22.7 million, 4.52% down from the prior year.
  • Non-Current Assets reached $23.4 million in Q3 2025 per NWBO's latest filing, roughly flat from $23.4 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $24.1 million in Q3 2024 and bottomed at $19.2 million in Q1 2021.
  • Average Non-Current Assets over 5 years is $22.3 million, with a median of $22.9 million recorded in 2021.
  • Peak YoY movement for Non-Current Assets: surged 245.17% in 2021, then decreased 11.77% in 2022.
  • A 5-year view of Non-Current Assets shows it stood at $22.9 million in 2021, then fell by 4.25% to $21.9 million in 2022, then rose by 8.41% to $23.7 million in 2023, then dropped by 4.52% to $22.7 million in 2024, then rose by 3.29% to $23.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $23.4 million in Q3 2025, $23.4 million in Q2 2025, and $22.8 million in Q1 2025.